Table 4

MMR rates according to time of Peg–IFN-α2b exposure

Duration of Peg–IFN-α2b treatmentMMR at week 52, %
< 12 weeks (n = 21) 67 
12-25 weeks (n = 7) 86 
26-37 weeks (n = 6) 100 
≥ 38 weeks (n = 22) 91 
Duration of Peg–IFN-α2b treatmentMMR at week 52, %
< 12 weeks (n = 21) 67 
12-25 weeks (n = 7) 86 
26-37 weeks (n = 6) 100 
≥ 38 weeks (n = 22) 91 

Calculation according to an intention-to-treat analysis.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal